source
- uniQure shares tumble 41% after Huntington’s gene therapy misses primary endpointuniQure reported updated 48‑month data from its phase 1/2 trial of AMT‑130 in Huntington’s disease. The therapy showed a 44% slowing of disease progression on the composite Unified Huntington’s Dis…
- Midterm elections could reshape drug pricing, Medicaid funding and research support, industry leaders warnThe November midterm elections are set to influence major health-care policy debates in Washington, according to STAT+. Industry leaders say the outcome could affect Medicaid funding levels, the p…